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Abstract 
The size of in vitro engineered skeletal muscle tissue is limited due to the lack of a vascular network 
in vitro. In this paper, we report tissue engineered skeletal muscle consisting of human aligned 
myofibers with interspersed endothelial networks. We extend our bio-artificial muscle (BAM) model 
by co-culturing human muscle progenitor cells with human umbilical vein endothelial ce lls (HUVECs) 
in a fibrin extracellular matrix. First, the optimal medium conditions for co-culturing myoblasts with 
HUVECs were determined in a fusion assay. Endothelial growth medium proved the best compromise 
for the coculture, without affecting myoblast fusion index. Second, both cell types were cocultured in 
a BAM maintained under tension to stimulate myofiber alignment. We then tested different total cell 
numbers containing 50% HUVECs and found that BAMs with a total cell number of 2.106 resulted in 
well aligned and densely packed myofibers while allowing for improved interspersed endothelial 
network formation. Third, we compared different myoblast-HUVEC ratios. Including higher numbers 
of myoblasts improved endothelial network formation at lower total cell density, however 
improvement of network characteristics reached a plateau when 1.106 or more myoblasts were 
present. Finally, addition of Matrigel to the fibrin ECM did not enhance overall myofiber and 
endothelial network formation. Therefore, in our BAM model, we suggest the use of a fibrin 
extracellular matrix containing 2.106 cells of which 50-70% are muscle cells. Optimizing these co-
culture conditions allows for a physiologically more relevant muscle model and paves the way 
towards engineering of larger in vitro muscle constructs. 
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Introduction 
Skeletal muscle tissue has a capacity for self-renewal upon muscle injury, but when this is impaired, 
non-functional scar tissue replaces the damaged or lost muscle. Current therapeutic interventions 
include autologous muscle transpositions, but these are associated with donor-site morbidity and 
poor tissue survival and integration (1). As an alternative for autologous muscle transpositions, 
human skeletal muscle organoids can be created in vitro by tissue engineering. Next to potential 
applications in regenerative medicine, muscle organoids may also be used as an in vitro model for 
myogenesis or myopathology. 
Culture and differentiation of myogenic progenitor cells on natural and synthetic biodegradable 
scaffolds (2,3) results in differentiated myofibers which are often unaligned. Parallel alignment of the 
myofibers can be induced when cells are subjected to a unidirectional force during differentiation 
and results in functional bio-artificial muscles (BAMs) which can be electrically and mechanically 
stimulated (4–6).  
However, the size of in vitro created skeletal muscle tissue is limited due to the lack of  a vascular 
network in vitro. Coculturing endothelial cells and myoblasts, muscle precursor cells, might overcome 
this problem. This way, the newly formed muscle can be prevascularized, meaning that an 
endothelial network is formed in vitro in the tissue engineered muscle. The goal is to anastomose this 
network to the host vasculature after transplantation. Although prevascularization of tissue 
engineered muscle has been described on scaffolds (7,8) ,  myofibers do not align in one direction on 
these scaffolds, precluding muscle contractility. Other tissue engineering approaches such as the use 
of soft hydrogels, the combination of endothelial cell sheets with myoblast cell sheets and 
microfabrication techniques such as 3D-printing may be more suitable to obtain aligned myofibers 
(7,9–13). Engineering muscle precursor cells in a soft hydrogel such as fibrin allows the myofibers to 
align in one direction while fibrin behaves pro-angiogenic, making it a good scaffold for both the 
formation of myofibers and endothelial networks.  
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Prevascularization of aligned tissue engineered muscle tissue has been described for murine muscle 
based on coculture of C2C12 murine myoblasts and embryonic heart endothelial cells  (14). Another 
report describes the engineering of aligned, functional rat muscle with post-implantation vascular 
integration in mice (15). To our knowledge however, prevascularization of human aligned myofibers 
has not been described. In this work, we aimed to determine suitable culture conditions allowing 
both aligned myofiber formation and endothelial network formation as a first step towards a human 
vascularized BAM. Therefore, we used a coculture of human muscle cells, containing both myoblasts 
and fibroblasts, and human umbilical vein endothelial cells (HUVECs) in a fibrin extracellular matrix.  
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Methods 
Cell culture. HUVECs labeled with Green Fluorescent Protein (GFP) (Angio-proteomie) were cultured 
on gelatin-coated culture flasks (0.1% gelatin, Millipore, pre-incubate for 1 hour at 37°C) in 
endothelial growth medium (EGM-2 with bullet kit, Lonza). GFP-HUVECs were split at 90% confluence 
and used in the experiment at passage 7. Human muscle cells (gift from H. Vandenburgh, Brown 
University, USA) were isolated by needle biopsy on a 27-year-old male volunteer from a muscle 
biopsy (vastus lateralis) according to procedures approved by the Institutional Clinical Review Board 
of the Miriam Hospital (Providence RI USA). They were cultured in Skeletal muscle Growth Medium 
(SkGM, Lonza), supplemented with 15% Fetal bovine serum (FBS, Lonza). Muscle cells were split at 
60-70% confluence and used in experiments at 21 doublings.   
3D tissue construct. Muscle cells and GFP-HUVECs were mixed with 500 µl thrombin (4 U/ml, 
Tissucol) and cast into 25-mm-long silicone rubber molds with end attachment sites. Then, 500 µl 
fibrinogen (2 mg/ml, Tissucol), with or without the addition of 20% Matrigel (BD Biosciences), was 
added and the cell-gel mix was mixed by quickly pipetting up and down, to form a fibrin gel (1 mg/ml, 
with or without 10% Matrigel) including both cell types. Following two hours incubation at 37°C, 
EGM-2 or SkGM medium supplemented with fibrinolysis inhibitors aprotinin (92.5 µg/ml Carl Roth) 
and tranexamic acid (400 µM, Sigma) was added and replaced every two days. For BAMs containing 
only muscle cells, the medium was switched to differentiation medium two days after casting (SkFM; 
DMEM with 10 ng/ml hEGF, 10 µg/ml insulin, 50 µg/ml BSA and 50 µg/ml gentamicin). BAMs were 
made with different cell type ratios and numbers. Medium was replaced every 2 days and BAMs 
were kept in culture for 7 days prior to thickness measurement and fixation. 
Thickness measurements. Cross-sectional thickness of BAMs in culture was measured with a sterile 
micrometer at day 7 after casting.  
Immunocytochemistry. Immunocytochemistry was performed in order to (i)  determine the amount 
of myoblasts and fibroblast in the cell population and (ii) to characterize the fusion index of the 
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myoblasts. For desmin staining, muscle cells were cultured in SkGM in 12-well dishes for 2-3 days 
until 60-70% confluent. For determination of fusion index, the cells were cultured to 80% confluence 
in SkGM and then switched to SkFM for 4 days to induce fusion into myofibers. Fixation was 
performed in a 1:1 methanol-aceton mix at -20°C for 10 min. Next, cells were permeabilized in 
blocking buffer containing 0.2% Triton-X-100 (Sigma) and 1% bovine serum albumin (BSA, Sigma) in 
PBS (30 min, RT). Subsequently, cells were incubated for 2 hours (RT) with a monoclonal mouse 
antibody against desmin (Sigma, D1033, 1:200 in blocking buffer) or tropomyosin (Sigma, T9283, 
1:100 in blocking buffer) to determine the myoblast percentage and the fusion index respectively. 
Cells were labeled with a polyclonal goat anti-mouse secondary antibody  (Alexa Fluor 568, A11004, 
Invitrogen) for 30 minutes in the dark and subsequently incubated with DAPI (0.1 µg/ml in PBS, Life 
Technologies) for 1 hour. The percentage of myoblasts in a muscle cell population was defined as the 
ratio of desmin positive cells to the total amount of cells (identified by the DAPI-stained nuclei). 
Fusion index was defined as the ratio of tropomyosin positive cells to the total amount of myoblasts 
in the population.  
Whole mount immunofluorescence staining and confocal microscopy. Constructs were washed (3x 
15 min in PBS) and then removed from the attachment sites. Then, they were pinned on styrofoam 
to preserve their original shape while fixing in 4% formaldehyde (Merck) for 1 h  and stored at 4°C in 
PBS. Immediately before whole-mount staining, samples were fixed a second time in -20°C methanol 
for 10 minutes and permeabilized in blocking buffer for 1 hour. Subsequently, BAMs were incubated 
overnight at 4°C with a monoclonal mouse antibody against tropomyosin (Sigma, T9283, 1:100 in 
blocking buffer). Next, BAMs were washed and incubated with a polyclonal goat anti-mouse 
secondary antibody (Alexa Fluor 568, A11004, Invitrogen, 1:200) for 30 minutes in the dark, followed 
by incubation with DAPI (Life Technologies, 0.1 µg/ml in PBS) for 1 hour. BAMs were stored in PBS in 
the dark until visualized. 
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Confocal imaging and data analysis. BAMs were placed on coverslips and visualized by confocal 
microscopy (Zeiss LSM710) within 48 hours. Per BAM, 5 z-stacks were acquired, each containing 20-
40 images (depending on the intensity of the signal at various depths) every 5 µm towards the center 
of the BAM. For myofiber analysis, each 20 µm z-projection (image grouping performed by the 
ImageJ software (16)) was manually analyzed for different parameters of myofiber formation: 
myofiber alignment, length and diameter as well as number of myofibers per microscopic field. 
Myofiber alignment was determined by the standard deviation of the angles of the myofibers. A 
lower number thus indicates better alignment. For endothelial network analysis, each 60 µm z-
projection was automatically analyzed by a customized version of the “Angiogenesis Analyzer”, an 
ImageJ plugin created by Gilles Carpentier (17). This tool quantifies endothelial networks in an 
objective manner, by extracting characteristic information of the network. Parameters to define 
endothelial networks were: junctions (group of joined nodes, pixels with at least 3 neighbors), 
branches (elements delimited by a junction and one extremity), isolated segments (binary lines which 
are not branched), total length of endothelial network (interconnected segments, branches and 
isolated segments), % branching length (length of interconnected segments and branches divided by 
total network length) and meshes (areas enclosed by segments) (Figure S1).  
Statistics. Number of replicates refers to number of analyzed images for microscopic analyses or to 
number of BAMs for thickness analyses. D’Agostino & Pearson normality test and Bartlett’s test were 
used to verify normality of the data and equality of variances, respectively. Normally distributed data 
with equal variances were analyzed by an unpaired student t-test when two groups were compared. 
For comparing several normally distributed groups, a one-way ANOVA was used with a Bonferroni 
multiple comparison post test. For groups that were not normally distributed and/or had unequal 
variances, a non-parametric Mann-Whitney test was used for comparison between two groups while 
Kruskal-Wallis test followed by a Dunn’s post test was performed for multiple comparisons. All values 
were expressed as mean ± standard deviation. * p< 0.05, ** p< 0.01, *** p< 0.001. 
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3. Results 
3.1 Aligned myofibers are formed in fibrin BAMs cultured in EGM-2 
We first characterized the cells expanded from human muscle biopsy. The myogenic progenitor 
population (further referred to as ‘muscle cells’) contained 92.1 ± 4.0% (n=15) myoblasts and 7.9 ± 
4.0% fibroblasts as assessed by desmin staining. Myoblasts had a fusion index of 70.0 ± 5.7% (n=20) 
as determined by tropomyosin staining. To make BAMs, 1.106 of these cells were mixed in a fibrin 
ECM (1mg/ml) and cultured in growth medium (SkGM) for 2 days, followed by differentiation 
medium (SkFM) for 5 days. The cell-ECM mix contracted around 2 attachment sites and formed 2-cm 
long muscle organoids (Figure 1, inset) containing aligned myofibers (Figures 1A, 1B and 2A).  
Aiming at the formation of endothelial networks and aligned myofibers in BAMs, cocultures of 
HUVECs and muscle cells were mixed in a fibrin ECM in a 50:50 ratio. They are further referred to as 
coculture BAMs, in contrast to regular BAMs that do not contain endothelial cells. To investigate if 
endothelial networks can be formed in these organoids, we first applied the same tissue-engineering 
procedure to cocultures of the muscle cells and endothelial cells. However, culturing 5.105 muscle 
cells and 5.105 GFP-HUVECs under these culture conditions resulted in poor survival of HUVECs as 
assessed by confocal fluorescence microscopy (data not shown). Since HUVECs are cultured in EGM-2 
medium, muscle cell survival and proliferation in this medium was examined i n 2D. Muscle cells 
proliferated in EGM-2, although significantly slower (doubling time 39.71 ± 1.59 hours, n=9) 
compared to SkGM medium (30.34 ± 0.55 hours, n=9). Optimal differentiation conditions for 2D 
cultures are obtained by growing the muscle cells for 2 – 3 days in SkGM until 80% confluency, 
followed by 3-4 days in SkFM (SkGM-SkFM). Performing the differentiation in EGM-2 medium for 5 
days resulted in myofibers with significantly less nuclei per fiber (2.49 ± 0.10 nuclei per fiber, n= 29), 
compared to SkGM-SkFM differentiation  (7.06 ± 0.58 nuclei per fiber, n=18). However, the fusion 
index does not differ significantly between EGM-2 (0.61 ± .012, n=29) and SkGM-SkFM (0.67 ± 0.01, 
n=18). 
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Next, we compared myofiber formation in the 3D organoid with 1.106 muscle cells cultured in EGM-2 
medium versus SkGM-SkFM medium. Whole mount tropomyosin staining was performed to visualize 
the formation of myofibers. Multinucleated myofibers formed in both EGM-2 and SkGM-SkFM 
media. However, myofibers cultured in EGM-2 contained a significant lower number of nuclei per 
myofiber (2.29 ± 0.10, n=10)  compared to those cultured in SkGM-SkFM (3.09 ± 0.15, n=10)  (Figure 
2). Culturing BAMs in EGM-2 also decreased the diameter of the formed myofibers. On the other 
hand, there was no significant difference between the use of the two media in the number and 
length of myofibers and the alignment factor (Table 1 columns A and D).  Also, the total thickness of 
the fibrin BAMs with 1.106 muscle cells was similar in SkGM-SkFM (2.48 ± 0.224 mm, n=3) versus 
EGM-2 (2.76 ± 0.159 mm, n=3). Since EGM-2 allowed culturing of muscle cells and HUVECs with 
formation of myofibers while enabling an optimal survival of the HUVECs, we further optimized 
coculture BAMs in EGM-2 medium. 
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3.2 Formation of aligned myofibers and endothelial networks in fibrin BAMs with a coculture of 
muscle cells and HUVECs 
Coculture BAMs with 50% endothelial cells were further studied in EGM-2 medium with different 
total cell numbers (Figure 3). The thickness of the BAM was inversely proportional with the total 
number of cells used, both in BAMs with and without HUVECs (Table 2 column A).  
BAMs and coculture BAMS, containing the same number of muscle cells (5.105 or 1.106), showed 
similar myofiber formation and alignment (Table 1 columns B-C and D-E, Figure S2). Myofibers were 
better aligned and more densely packed in coculture BAMs with a higher total cell number of 2.106 
versus 1.106 (Figure 3). Compared to coculture BAMs with a total number of 1.106, coculture BAMs 
with 2.106 cells showed a significant increase in myofiber density and alignment (Table 1 columns C 
and E, Figure S2, Video S1). We hypothesized that also endothelial network formation would be 
enhanced. Indeed, the endothelial networks were significantly improved in the coculture BAMs with 
2.106 cells (Figure 4, Table 3 column A and D, Figure S3, Video S2). The presence of meshes was 
detected in coculture BAMs and confirms formation of extended endothelial networks (Figure 3, 
Figure 4). 
 
3.3 30% HUVECs suffice to induce endothelial networks between aligned myofibers  
Based on our previous findings and on research from other groups (7,9,18), we started experiments 
with coculture BAMs with a ratio of 50% muscle cells and 50% HUVECs to obtain myofiber and 
endothelial network formation. To optimize this ratio, BAMs with a total of 1.106 or 2.106 cells were 
made with different ratios, ranging from 50-70% muscle cells and 50-30% HUVECs.  
In coculture BAMs with a total of 1.106 cells, a muscle cell:HUVEC ratio of 60:40 or 70:30 showed 
significant better endothelial network formation, compared to coculture BAMs with a 50:50 ratio 
(Table 3 columns A-C, Figure 4, Figure S3). Although there was a trend towards further improvement 
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of the endothelial network formation in the 70:30 ratio compared to the 60:40 ratio, this was not 
significantly different. In the condition with a high percentage of HUVECs (50%), dense clusters of 
HUVECs occurred at certain places on the surface of the BAMs, which could not be analyzed by 
Angiogenesis Analyzer. When a total number of 2.106 cells was used, all ratios performed equally well 
(Table 3 columns D-F). However, when compared with the same ratio in BAMs with 1.106 cells, there 
was a significant improvement in endothelial network formation for each ratio, indicating that 
increasing the total cell number to 2.106 is beneficial for all ratios studied (Video S2). The dense 
clusters of HUVECs mentioned above were not observed in BAMs with a total cell count of 2.106 cells. 
In coculture BAMs with a total of 1.106 cells, a ratio of 60:40 or 70:30 also showed significant better 
myofiber formation, compared to coculture BAMs with a 50:50 ratio: there was a significant increase 
in myofiber density and alignment (Table 4 columns A-C, Figure S4).  When a total cell number of 
2.106 was used, no major changes towards improvement of myofiber formation could be detected 
with increasing ratios of myoblasts (Table 4 columns D-F, Figure S4). When comparing the same 
ratios in BAMs with 1.106 versus 2.106 cells, there only was a consistent improvement in alignment of 
myofibers for the BAMs with 2.106 cells. 
  
 Page 12 of 50
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
En
do
th
el
ia
l n
et
w
or
k 
fo
rm
at
io
n 
w
ith
in
 h
um
an
 ti
ss
ue
-e
ng
in
ee
re
d 
sk
el
et
al
 m
us
cl
e 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
15
.00
93
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
13 
 13 
3.4 Matrigel impacts myofiber distribution, but does not improve myofiber and endothelial 
network formation  
In tissue engineering, Matrigel is often used as a (component of) hydrogel, because it contains a 
complex mixture of extracellular matrix components and growth factors and has a beneficial impact 
on tissue growth in vitro (1,14).  We hypothesized that addition of Matrigel to the fibrin ECM might 
enhance myofiber and endothelial network formation. 
We assessed the addition of 10% Matrigel to the ECM of fibrin. This did not significantly change the 
thickness of the BAMs, neither in BAMs with 1.106 muscle cells, neither in coculture BAMs with 5.105 
muscle cells and 5.105 HUVECs (Table 2). 
While in BAMs with 1.106 muscle cells in fibrin only, myofibers are evenly distributed throughout the 
BAM, the addition of 10% Matrigel to the ECM causes an uneven distribution and formation of 
myofibers. An outer region of 20-30 µm was observed, containing densely packed and highly aligned 
myofibers and a core with lower cell density containing significantly lower length and alignment of 
myofibers (Table 1, compare columns F - G with column D, Figure S5). 
Compared to the homogenously distributed fibrin BAMs, the outer densely packed region shows 
significantly longer myofibers, but there is no significant difference in alignment, fiber diameter or 
number of myofibers (Table 1, column F versus D). The inner region contains myofibers that are less 
well aligned with no significant difference in the other parameters (Table 1, column G versus D). To 
conclude, the addition of 10% Matrigel does not result in a better myofiber formation throughout 
the entire BAM, but only in a small outer region of the BAM. In contrast, a decreased myofiber 
alignment is observed in the inner region. Overall, myofiber formation is heterogeneous throughout 
the BAM in the presence of Matrigel in the ECM.  
  
 Page 13 of 50 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
En
do
th
el
ia
l n
et
w
or
k 
fo
rm
at
io
n 
w
ith
in
 h
um
an
 ti
ss
ue
-e
ng
in
ee
re
d 
sk
el
et
al
 m
us
cl
e 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
15
.00
93
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
14 
 14 
Discussion 
Obtaining thicker tissue engineered constructs is one of the important goals in the field of tissue 
engineering. In order to succeed, vascularization is essential for obtaining viable constructs with 
increased survival time in vitro and improved engraftment upon transplantation (7,9,18). To do this, 
networks of endothelial cells, which form the innermost layer of blood vessels, must be established 
within the tissue engineered muscle. The current BAM model consists of aligned multinucleated 
myofibers, without endothelial cells, starting from a population of human myoblasts and fibroblasts 
cast in ECM (19). We used the natural hydrogel fibrin as a scaffold for the cells rather than collagen 
or other alternatives. This choice was made because of its stiffness characteristics and angiogenic 
properties (20–24). The formation of 3D tissue engineered human muscle in a fibrin ECM was already 
described in detail before, however endothelial cells were not present in these 3D cultures (24). In 
our work, HUVECs were added to the muscle cell – fibrin mix to obtain endothelial networks between 
the myofibers. HUVECs are relatively easy to obtain from umbilical cord, are robust in culture and are 
capable of endothelial cell tube formation in vitro (25,26). Adding multiple cell types in an organoid 
presents a challenge regarding culture conditions (27). Also in our system, culture conditions needed 
to be modified to sustain growth and differentiation of both cell types. We observed that endothelial 
cells fail to survive and form networks in the optimal culture condition for fibrin BAMs in skeletal 
muscle growth and differentiation medium. Therefore, we analyzed myofiber formation in BAMs 
cultured in EGM-2, a growth medium optimized for endothelial cells.  This resulted in thinner 
myofibers with fewer nuclei per fiber, compared to the original medium. This may be explained both 
by a decreased proliferation of myoblasts during the first 2 days in EGM-2 versus SkGM, resulting in a 
lower cell density and a decreased myoblast fusion in EGM-2 as observed by a lower number of 
nuclei per myofiber. Nevertheless, aligned myofibers were still formed in BAMs cultured in EGM-2 
medium while allowing the survival of HUVECs, making it the preferred medium for sustaining 
coculture BAMs.  
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Next, we investigated varying total cell numbers per BAM and different ratios of HUVECs versus 
muscle cells to determine the impact on endothelial network formation as well as myofiber 
formation. For BAMs with 1.106 total cells and 50% HUVECs, limited branching and mesh formation 
was observed. Network characteristics could be improved in cocultures with 40 or even 30% 
HUVECS. These endothelial networks have a higher number of branches and junctions and a lower 
number of isolated segments compared to the 50% HUVEC BAMs. The biggest improvement however 
was observed when a total cell number of 2.106 was used instead of 1.106 (Video S2). In these BAMs, 
the total length of the endothelial network doubled, concurrent with a higher number of meshes, 
branches and junctions and a lower number of isolated segments. For 2.106 cells, there was no 
further improvement when the muscle cell :HUVEC ratio was increased from 50:50 to 60:40 or 70:30. 
This suggests that for the given system and conditions tested a maximal endothelial network 
formation was reached when 2.106 cells were used, independent of the muscle cell:HUVEC ratio. Also 
for myofiber formation, the 30% and 40% HUVEC BAMs with a total cell number of 1.106 contained a 
higher number of myofibers that were thicker and better aligned than in the 50% HUVEC BAMs. 
Moreover, in the 50% HUVEC BAMs, HUVECs were unequally distributed throughout the BAM with 
denser layers towards the surface. These dense layers of HUVECs were not observed in the 
conditions with 2.106 cells, pointing to a better distribution of the HUVECs within the BAM. Overall, 
parameters of myofiber formation performed equally well or better when using 2.106 cells versus 
1.106 cells. Similar to endothelial network formation, changing the muscle cell:HUVEC ratio did not 
further influence myofiber formation for 2.106 total cells. These and the above findings suggest an 
optimal combination of myofiber and endothelial network formation in coculture BAMs with 2.106 
cells and a minimum of 50% muscle cells (Video S3). The presence of 1.106 muscle cells (both in 
BAMs with or without endothelial cells) has a double advantage over BAMs with only 5.105 muscle 
cells. First, as can be expected when using more muscle cells, myofiber density is higher. Second, a 
concurrent positive effect is observed in the alignment of myofibers. At the tissue level, BAMs with a 
higher total cell number have a significantly smaller thickness, regardless of the type of cells. This 
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may be explained by an augmented cell-mediated contraction of the ECM. We can conclude that the 
presence of HUVECs does not impair the formation of myofibers.  
In addition to a better endothelial network formation when doubling total cell number per BAM, an 
increased amount of muscle cells has an important effect on endothelial network formation in the 
presence of similar amounts of HUVECs (compare Table 4 column A vs column F). It has been 
described that VEGF is also produced by myoblasts and this expression is enhanced when myofibers 
are kept under uniaxial tension (14). In the experiments described in this paper, we used endothelial 
growth (EGM-2) medium, which contains 0.5 ng/ml VEGF. Addition of VEGF in constructs with only 
endothelial cells lead to a more organized growth pattern of the endothelial cells (14). Although the 
amount of VEGF secreted by the myofibers in the cell culture medium (< 0.3 ng/ml) (14) was much 
lower than the amount of VEGF present in EGM-2 medium, local VEGF concentrations in our 
extracellular fibrin matrix may be much higher because of VEGF binding to fibrin (28). This is 
consistent with the observation that even lower total amounts of HUVECs still result in better 
endothelial network formation when total cell number is kept at 1.106, since the total amount of 
myofibers is higher.  
In none of the myofibers we visualized, we could detect cross-striations. These have been described 
in vitro both in 2D (29) as well as in 3D muscle cultures (30,31). We performed confocal microscopy 
at day 7 of cocultures, whereas cross-striations were reported only after 14 days of culture. Next to a 
prolonged culture time, supplementing EGM-2 medium with specific growth factors to stimulate 
myoblast fusion such as MAGIC-F1 protein, IGF-1 and follistatin (32), can be explored in the future. 
Also, subjecting BAMs to electrical and/or mechanical stimulation has been described to further 
improve several muscle characteristics such as viscoelastic properties, protein synthesis, myofiber 
diameter and density, thus improving the level of maturation of myofi bers (33,34).  
Next to HUVECs, other endothelial cell populations may be worthwhile further investigation. In 
particular, endothelial colony forming cells (ECFCs), also termed blood outgrowth endothelial cells 
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(BOECs), are able to perform de novo tube formation and are pro-angiogenic in vitro and in vivo (35). 
Human peripheral blood and umbilical cord blood ECFCs form de novo functional blood vessels when 
seeded into a matrix and implanted in vivo (36). Microvessel density was similar for ECFCs and 
HUVECs, indicating a robust vasculogenic potential for both cell types (37). Adult peripheral blood 
ECFCs formed unstable vessels, while umbilical cord blood derived ECFC transiently formed vessels 
when implanted alone and were stable for four months when co implanted with fibroblasts in an 
immunodeficient recipient (38). Our muscle cell population also contains fibroblasts. These have 
been described to provide support for endothelial cells as well as modulate their migration, viability, 
and network formation (39). Optimizing fibroblast ratios and/or using other cell populations such as 
pericytes to stabilize endothelial networks may also further improve the cocultures (40). It remains to 
be seen though if the type of endothelial cells which are used in vitro is a critical factor once the 
construct is implanted, since the implanted endothelial network may be replaced by the host. 
Engineered human vascular networks, which were transplanted into third-degree burns connected 
with the host vessels during the first week, but during a remodeling phase in the second week after 
transplantation, the transplanted vessels regressed (41) and were replaced by host vessels. 
Transformation into mature blood vessels occurs via an inflammation-mediated process of vascular 
remodeling (42).  
As described by others (7,9,11,18), prevascularization of tissue engineered muscle improves 
vascularization, blood perfusion and survival of the muscle constructs upon transplantation. 
Specifically, Koffler and colleagues (18) have shown that the degree of prevascularization in vitro, 
which highly depends on ECM, cell types, cell number, culture conditions and duration of in vitro 
culture, determines the in vivo vascularization. The goal of our study was to optimize experimental 
conditions in order to obtain maximal endothelial network formation in coculture BAMs. These 
findings open perspectives towards culture of larger, prevascularized BAMs with potential for human 
muscle transplantations as well as a physiologically relevant in vitro model for studying diseases and 
therapies (5,43,44). Host blood vessels are able to invade avascular muscle bundles (45), however 
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this still limits the size of muscle bundles that can be kept in culture pre -implantation. Ideally, 
anastomosis of the pre-implantation network with host vessels occurs. Anastomosis between 
HUVEC-derived vessels and host (mouse) vessels has been detected (46) and this occurs as early as 1 
day after implantation (18), although it is not clear to what extent anastomosis occurs. Whether our 
prevascularized BAMs survive in vivo and allow for anastomosis will be assessed by future 
implantation experiments.  
We also tested the addition of 10% Matrigel in coculture BAMs. Matrigel has been used in 
combination with collagen type I to form BAMs (19). It is a gelatinous protein mixture obtained from 
mouse sarcoma cells containing many ECM-proteins and growth factors. Fibrin (1 mg/ml) without 
Matrigel supports a homogenous formation of myofibers. In contrast, in the BAMs with 10% 
Matrigel, the myofibers in the exterior 20 µm of the BAM are longer than in the condition without 
Matrigel. In the center of the BAM, the myofibers are less well aligned compared to the fibrin-only 
ECM. To conclude, we do not suggest using Matrigel as part of the ECM of BAMs with a fibrin-based 
ECM, in order to obtain homogenously distributed and formed myofibers. Moreover, the 
composition of Matrigel is not fully characterized.  
In addition, different gel formulations and gelation conditions can strongly influence fibrin 
biochemistry and ultrastructure, which in turn has an important effect on its angiogenic properties 
and on cell behavior (47). Fibrin ultrastructure (and cell behavior) is also affected by fibrinogen and 
thrombin concentrations, calcium ion content, ionic strength, temperature, and pH during gelation. 
For both thrombin and fibrinogen, there is not only a difference between brands, but also within one 
brand depending on the source of the fibrin (47). Therefore, a direct comparison of these results with 
previous results in literature is difficult, since different research groups not only use different types 
of fibrin, but also different cell types, cell numbers and volumes of ECM in tissue engineering of 
BAMs (5,7,9,12,18–20). 
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In order to create muscle tissue similar to that in the adult body, still other hurdles nee d to be 
overcome. A major one is the formation of neuromuscular synapses. Therefore, myofibers should 
express functional nicotinic acetylcholine receptors (AchR) capable of generating acetylcholine 
induced action potentials. Acetylcholine receptor expression increases sharply just before myoblast 
fusion (48), but is distributed randomly along the surface. During later phases of myogenesis, these 
receptors cluster at the motor endplates. In the absence of neural cells, BAMs have been shown to 
form mature AchR clusters by the addition of agrin and laminin (49). In the absence of mature AchR 
clusters, BAMs can still be stimulated by electrical current, which results in increased protein 
synthesis, increased force production and excitability (5,50). The introduction of neural cells to a 
monolayer of myotubes resulted in the formation of neuromuscular-like junctions with clustering of 
acetylcholine receptors (51). It is not known whether endothelial cells could affect the expressi on of 
muscle nicotinic receptors and/or induce clustering of AchR. This could be further studied with our 
coculture system. Furthermore, BAMs should remain under tension in vivo in order to avoid atrophy. 
Therefore, another issue to be addressed is the integration of BAMs with (bio-artificial) tendons. Our 
model system allows for extensive biochemical, physical, cellular and electrical characterization of 
the effect of adding different cell types to muscle cells during myofiber formation. It thus bridges th e 
gap between 2D culture systems and in vivo transplantation of exogenous muscle tissue. 
To our knowledge, we have tissue engineered for the first time a human bio-artificial muscle 
containing advanced endothelial cell networks by coculturing HUVECs and human muscle cells in a 
fibrin ECM.  
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Figure 1. H&E staining of a bio-artificial muscle (BAM) with 1.106 muscle cells in a fibrin extracellular 
matrix shown with a 10x (A) and 40x (B) objective. Inset shows a seven-day old BAM in a 6-well plate, 
fixed to two attachment sites which are 2 cm apart. Myofibers are aligned and homogenously 
distributed over the entire BAM. Scale bars represent 50 (A) and 10 µm (B).   
  
 Page 27 of 50 
Ti
ss
ue
 E
ng
in
ee
rin
g 
Pa
rt 
A
En
do
th
el
ia
l n
et
w
or
k 
fo
rm
at
io
n 
w
ith
in
 h
um
an
 ti
ss
ue
-e
ng
in
ee
re
d 
sk
el
et
al
 m
us
cl
e 
(do
i: 1
0.1
08
9/t
en
.T
EA
.20
15
.00
93
)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
28 
 28 
 
 
Figure 2. Multinucleated myofibers in BAMs with 1.106 muscle cells, cultured in (A) SkGM-SkFM and 
(B) EGM-2 medium. Blue: nuclei stained with DAPI; red: myofibers stained with tropomyosin 
immunofluorescence.  
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Figure 3. Fluorescent confocal images of coculture BAM with 50% HUVECs and 50% muscle cells and 
a total cell number of 1.106 cells (A) and 2.106 cells (B). Endothelial networks (green) between aligned 
myofibers (red) in 3D (left) and an xy-cross section in 2D (right). Scale bars represent 50 µm, meshes 
are indicated by arrows.  
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Figure 4. (A) Analysis by Angiogenesis Analyzer ImageJ’s plugin, visualizing endothelial network 
formation of 60 µm z-projection images of fibrin BAMs with a total of 1.106 cells with 50%  (A), 40% 
(B) and 30% (C) HUVECs or with a total of 2.106 cells with 50%  (D), 40% (E) and 30% (F) HUVECs.  
Angiogenesis Analyzer indicates master junctions (pink dots), master segments (yellow), meshes 
(light blue), branches (green) and isolated segments (blue). Scale bar represents 50 µm.  
Table legends 
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Table 1. Myofiber formation in fibrin BAMs with only muscle cells (5.106 or 1.106 cells) or coculture 
BAMs with 50% HUVECs and 1.106 or 2.106 cells in total, cultured in SkGM-SkFM (column A) or EGM-
2 medium (columns B-G) for 7 days. Columns A–E are discussed and compared in section 3.1, 
columns F– G are discussed in section 3.4. In the last 7 columns, statistical significances are shown for 
comparisons of indicated groups. Multiple comparisons were made by a Kruskal Wallis test followed 
by a Dunn’s post test except for the parameter diameter where a parametric ANOVA followed by a 
Bonferroni post test was used.  
Table 2. Thickness (in mm) of different fibrin BAMs, cultured for 7 days in EGM-2 medium. In section 
3.2, only column A is discussed. In section 3.4, a comparison is made between column A and B.  
Table 3. Parameters characterizing the formation of endothelial networks in fibrin coculture BAMs 
with a total of 1.106 cells with 50%  (A), 40% (B) and 30% (C) HUVECs or with a total of 2.106 cells with 
50%  (D), 40% (E) and 30% (F) HUVECs .In the last 5 columns, statistical significances are shown for 
comparisons of indicated groups. Comparisons B-C, D-E, D-F and E-F were also made but did not 
result in statistically significant differences for any of the parameters. For multiple comparisons 
within groups (1.106 total cell count (A, B and C) or 2.106 total cell count (D, E and F)), a 
nonparametric Kruskal-Wallis test with Dunn’s post test was used. For pairwise comparisons 
between groups (A-D, B-E and C-F), a Mann Whitney test was performed. 
Table 4. Parameters characterizing the formation of myofibers in fibrin coculture BAMs with a total 
of 1.106 cells with 50%  (A), 40% (B) and 30% (C) HUVECs or with a total of 2.106 cells with 50%  (D), 
40% (E) and 30% (F) HUVECs. In the last 9 columns, statistical significances are shown for 
comparisons of indicated groups. For multiple comparisons within groups (1.106 total cell count (A, B 
and C) or 2.106 total cell count (D, E and F)), a nonparametric Kruskal-Wallis test with Dunn’s post 
test was used. For pairwise comparisons between groups (A-D, B-E and C-F), a Mann Whitney test 
was performed. 
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Table 1 
  A (n=12) B (n=8)  C (n=11) D (n=10) E (n=34)  F (n=11)  G (n=75) A-D B-C D-E C-E B-D D-F D-G 
# Myoblasts 1.10
6
 5.10
5
 5.10
5
 1.10
6
 1.10
6
 1.10
6
 1.10
6
 
              
# HUVECs 0 0 5.10
5
 0 1.10
6
 0 0 
Medium SkGM/SkFM EGM-2 EGM-2 EGM-2 EGM-2 EGM-2 EGM-2 
            
+10% matrigel 
outer 20 µm 
+10% matrigel 
inner 140 µm 
Number/microscopic 
field 
42.20 ± 7.64 21.51 ± 2.34 25.63 ± 10.02 39.96 ± 5.75 40.48 ± 10.25 37.09 ± 17.14 35.21 ± 8.24 NS NS NS ** * NS NS 
Alignment  10.34 ± 4.95 11.36 ± 4.00 16.24 ± 5.96 8.04 ± 1.89 5.09 ± 1.33 7.51 ± 3.76 14.07 ± 4.45 NS NS NS *** NS NS *** 
Length (µm) 147.60 ± 14.11 118.7  ± 16.30 118.90  ± 6.93 126.30  ± 7.02 127.4 ± 37.56 176.30  ± 52.45 113.40 ± 21.21 NS NS NS  NS NS *** NS 
Diameter (µm) 15.34 ± 3.78 10.81 ± 4.26 12.79 ± 4.60 12.20 ± 3.00 13.26 ± 3.69 14.27 ± 3.22 13.75  ± 3.67 * NS NS  NS NS NS NS 
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Table 2 
 A. Fibrin ECM B. Fibrin + 10% matrigel ECM 
5.10
5
 muscle cells 3.20 ± 0.07 (n=3) 3.23  ± 0.35 (n=3) 
1.10
6
 muscle cells 2.48 ± 0.39 (n=3) 3.32  ±0.13 (n=3) 
5.10
5
 muscle cells + 
5.10
5
 GFP-HUVECs   
2.20 ± 0.36 (n=3) 2.20  ±0.18 (n=3) 
1.10
6
 muscle cells + 
1.10
6
 GFP-HUVECs  
1.27 ± 0.22 (n=12) ND 
12.10
5
 muscle cells + 
8.10
5
 GFP HUVECs 
1.30 ± 0.03 (n=4) ND 
14.10
5
 muscle cells + 
6.10
5
 GFP HUVECs 
1.28 ± 0.21 (n=4) ND 
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Table 3 
 A (n=37) 
 
B (n=8) 
 
C (n=5) 
 
D (n=219) 
 
E (n=65) 
 
F (n=50) A-B A-C A-D B-E C-F 
Total # cells in BAM 1.106 1.106 1.106 2.106 2.106 2.106      
# Muscle cells 5.105 6.105 7.105 10.105 12.105 14.105      
# HUVECs 5.105 4.105 3.105 10.105 8.105 6.105      
% branching length 20.96 ± 13.28 39.05 ± 15.67 48.29 ± 8.19 76.36 ± 11.84 79.21 ± 8.01 75.92 ± 11.05 ** *** *** *** *** 
Number of isolated segments 51.24 ± 14.29 36.00 ± 8.40 29.60 ± 2.70 18.72 ± 9.89 15.37 ± 4.78 16.44 ± 5.41 ** *** *** *** *** 
Number of junctions 3.62 ± 2.64 7.63 ± 4.03 8.60 ± 2.61 47.43 ± 21.61 50.13 ± 13.54 49.64 ± 28.78 ** ** *** *** *** 
Number of branches 7.78 ± 4.92 15.13 ± 6.47 15.40 ± 5.37 45.96 ± 13.84 48.33 ± 9.68 46.14 ± 17.55 ** ** *** *** *** 
Total length (µm) 16422 µm ± 3591 20349 µm ± 5295 21488 ± 4574 38262 µm ± 7147 39920 µm ± 4942 40165 ± 8298 * * *** *** *** 
Number of meshes 0.49 ± 0.8035 0.75 ± 0.71  1.00 ± 0.70 10.50 ± 7.14 12.35 ± 5.182 12.38 ± 8.82  NS NS *** *** *** 
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Table 4 
 A (n=11) 
 
B (n=24) 
 
C (n=19) 
 
D (n=34) 
 
E (n=20) 
 
F (n=15) A-B A-C B-C D-E D-F E-F A-D B-E C-F 
Total # cells in BAM 1.106 1.106 1.106 2.106 2.106 2.106          
# Muscle cells 5.105 6.105 7.105 10.105 12.105 14.105          
# HUVECs 5.105 4.105 3.105 10.105 8.105 6.105          
Number/ 
microscopic field 
25.63 ±10.02 47.08 ±15.41 48.68 ± 12.56 40.48 ± 10.25 48.29 ± 13.62  49.16 ± 7.26  ** *** NS NS ** NS ** NS NS 
Alignment 16.24 ± 5.96 6.25 ± 0.84 7.72 ± 4.30 5.09 ± 1.33 3.65 ± 0.79 4.912 ± 1.12 *** * NS *** NS ** *** *** *** 
Length (µm) 118.90 ± 6.93 123.4 ± 13.9 119.7 ± 15.9 127.4 ± 37.56 121.3 ± 15.37 119.2 ± 13.18 NS NS NS NS NS NS NS NS NS 
Diameter (µm) 12.79 ± 4.60 16.88 ± 8.82 24.05 ± 7.18 13.26 ± 3.69 12.22 ± 2.88 11.96 ± 1.058 NS *** ** NS NS NS NS * *** 
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Figure S1. Quantification by Angiogenesis Analyzer (right) and original image (left) of endothelial 
network formation in a coculture BAM. In the right image, there is an indication of master junctions 
(pink dots), master segments (yellow), meshes (light blue), branches (green) and isolated segments 
(blue). Scale bar indicates 50 µm. 
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Figure S2. Myofiber formation in fibrin BAMs with 0.5 or 1.106 muscle cells with or without 0.5 or 
1.106 HUVECs, respectively.  
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Figure S3. Endothelial network formation  in coculture BAMs with different ratios of muscle cells and 
HUVECs in a total of 1.106 or 2.106 cells. This figure is a graphical representation of Table 3. 
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Figure S4. Myofiber formation in coculture BAMs with different ratios of muscle cells and HUVECs in 
a total of 1.106 or 2.106 cells. This figure is a graphical representation of Table 4.  
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Figure S5. BAM with 1.106 muscle cells in an ECM of fibrin +10% matrigel (A and B show outer and 
inner zone respectively) and in a fibrin ECM without matrigel (C). The outer zone of 20 – 30 µm with 
matrigel (A) shows well aligned myofibers which are longer than in the condition without matrigel (C) 
whereas the inner zone (B) shows less well aligned myofibers compared to the condition shown in 
(C). Tropomyosin staining (red) shows myofibers, DAPI (blue) shows cell nuclei.   
Video S1. Fluorescent confocal z-stack of aligned myofibers in coculture BAM with 50% HUVECs and 
50% muscle cells and a total cell number of 2.106 cells. This video is a rotating 3D reconstruction of 
Figure 3B.  
Video S2. Fluorescent confocal z-stack of endothelial networks in coculture BAM with 50% HUVECs 
and 50% muscle cells and a total cell number of 2.106 cells. This video is a rotating 3D reconstruction 
of Figure 3B.  
Video S3. Fluorescent confocal z-stack of coculture BAM with 50% HUVECs and 50% muscle cells and 
a total cell number of 2.106 cells. Endothelial networks (green) between aligned myofibers (red) in 
3D. This video is a rotating 3D reconstruction of Figure 3B.  
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